Cleaning Validation Hub
chevron left
Top 7 Mistakes in selecting Equipment Sampling Locations

Top 7 Mistakes in selecting Equipment Sampling Locations

October 9, 2024
8
 mins read

Discover the common pitfalls in selecting sampling locations for equipment cleaning validation in the pharmaceutical industry and learn how to avoid them for better compliance and safety.

Skipping Comprehensive Risk Assessment for Sampling Location Selection

The most glaring oversight in the industry is bypassing a comprehensive risk assessment when choosing equipment sampling locations. Such assessments should scrutinize equipment characteristics, including geometry, material, and ease of cleaning. A structured risk matrix, evaluating factors like dismantling complexity and residue detectability, can pinpoint 'hard-to-clean' areas, ensuring they adhere to the Maximum Safe Carryover (MSC) standards, as necessitated by regulatory bodies like the FDA (21 CFR 211.67). An in-depth evaluation should encompass factors such as dismantling complexity, cleanability, accessibility, and detectability. For example, using a risk matrix, a hopper could have varying Risk Priority Numbers (RPN) based on its design complexities and cleanliness challenges – such as an RPN of 256 for one hopper configuration versus a different score for another based on these criteria.

Inadequate Sampling of Areas — Understanding the Formula

Neglecting to sample adequately can invalidate your cleaning validation efforts. The extent of sampling is critical; it's not just about quantity but representativeness. The sampling formula crucial to this process is

, where 'e' is the margin of error and 'z' is the z-score. This formula helps determine the necessary sample size to ensure the entire equipment's cleanliness with statistical confidence.

Overlooking Indirect Product Contact Surfaces

A common misstep is ignoring surfaces that don't directly contact the product but are still critical, like lyophilizer shelves in proximity to open products. These areas, though indirect, can harbor contaminants and pose significant risks. The same stringent cleaning validation standards applied to direct contact surfaces should extend to these indirect areas to mitigate cross-contamination risks, following best practices as outlined in industry references like PDA TR 29. 

Over reliance on Rinse Samples without Swab Assessment

Relying solely on rinse samples without considering the swab sampling method falls short of thorough validation. The FDA's Q12 guideline emphasizes the necessity of direct methods, such as swabbing, for accurate residue detection on equipment surfaces. This approach ensures a more reliable and comprehensive assessment of the cleaning process's efficacy. FDA guidelines, particularly the Q&A on Current Good Manufacturing Practices—Equipment, advocate for direct methods to ensure comprehensive residue detection on equipment surfaces. Incorporating both rinse and swab samples provides a more complete contamination risk assessment, enhancing validation accuracy.

Not Accounting for Variations in Material Construction

Each material may interact differently with cleaning agents and contaminants, necessitating tailored cleaning protocols. For instance, validating a cleaning procedure for 316 stainless steel does not universally apply to other materials. Ignoring these variations can result in suboptimal cleaning outcomes. Validation processes must, therefore, be material-specific, addressing the unique challenges posed by different surfaces and designs to meet the stringent requirements 

Utilizing the Same Sampling Plan for Validation and Continuous Verification

A static sampling plan that does not evolve from validation to ongoing verification undermines process control. Unlike validation, continuous verification aims to monitor the cleaning process's efficacy over time, requiring a dynamic approach tailored to operational realities. This distinction ensures that the cleaning protocol remains robust and compliant with evolving production demands and regulatory expectations, as echoed in recent EMA guidelines.

Inconsistent Risk Assessment Practices Across the Organization

Discrepancies in risk assessment methodologies across different organizational units can lead to uneven standards and potential compliance gaps. A unified, organization-wide approach to risk assessment ensures consistent application of best practices, fostering a culture of quality and safety in line with global regulatory standards.

LEUCINE 10X LES
Experience the Future of Pharma
Integrate your entire shop floor in digital environment, uncover powerful insights and increase productivity.
FDA TRACKER
Free FDA Form 483 Analytics Tool
Mitigate compliance risks in your pharma processes with our large repository of in-depth insights
Related Resources

View and learn more about Cleaning Validation with our comprehensive list of resources

Leucine’s cleaning validation software supports your goal of 0 FDA Observations

Speak with one of the expert consultants at Leucine to know how.

Schedule Demo